At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 48 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Metastatic Non Small Cell Lung Cancer. Completed, enrolled 48 participants across 1 site.
Detailed Summary
Single arm one stage Phase II study: post 4-6 cycles platinum doublet chemotherapy for patients with metastatic Non Small Cell Lung Cancer (NSCLC) offering Pembrolizumab as maintenance therapy to non-progressors with primary endpoint: Immune Related Progression Free Survival (irPFS) at 1 year. Aim to show that this is at least 25% (compared to an expected 12% 1 year PFS based on the Pemetrexed and Erlotinib maintenance trials).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Non Small Cell Lung Cancer
CountriesCyprus
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 11, 2016
Enrollment StartApr 25, 2016
Primary CompletionMay 2, 2023
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 10.3 years ago
Interventions
Pembrolizumabdrug
Switch maintenance pembrolizumab treatment